Table 4.
Atezo plus Beva: updated results of ORR (phase 1b study: arm A)
| ASCO 2018 Atezo + Beva (n = 23)a | ESMO 2018 Atezo + Beva (n = 73)a | ESMO 2019 Atezo + Beva (n = 104)a | |
|---|---|---|---|
| ORR | 15 (65%) → | 20 (27%) → | 37 (36%) |
| CR | 1 (4%) | 4 (5%) | 12 (12%) |
| PR | 14 (61%) | 16 (22%) | 25 (24%) |
| SD | 7 (30%) | 35 (48%) | 37 (36%) |
| PD | 1 (4%) → | 14 (19%) → | 24 (23%) |
| DCRb | 22 (96%) | 55 (75%) | 78 (75%) |
Figures are presented as n (%). Atezo, atezolizumab; Beva, bevacizumab; ASCO, American Society of Clinical Oncology; ESMO, European Society for Medical Oncology; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate.
a
Independent review facility-assessed per RECIST v1.1.
b
CR + PR + SD.